Plain-English reading on the vagus nerve, its science and how to look after it
Conditions

The Impact of Vagus Nerve Stimulation on Rheumatoid Arthritis

A flat folk-art vector silhouette of a human hand with wild roses and buttercups behind it.

How Vagus Nerve Stimulation Treats Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disease driven by chronic inflammation in the joints. Standard treatment relies on immunosuppressive drugs — methotrexate, biologics like TNF inhibitors, JAK inhibitors — that suppress the entire immune system to control the inflammatory response. Vagus nerve stimulation (VNS) represents a fundamentally different approach: using electrical signals to modulate the immune system through the body’s own anti-inflammatory neural circuit, without systemic immunosuppression.

This approach, called bioelectronic medicine, is built on two decades of research into the cholinergic anti-inflammatory pathway, and is now being tested in clinical trials with promising results.

The Cholinergic Anti-Inflammatory Pathway

The scientific foundation for VNS in RA begins with a discovery by Kevin Tracey and colleagues at the Feinstein Institutes for Medical Research. In a landmark 2000 study, Tracey’s group demonstrated that electrical stimulation of the vagus nerve could suppress the production of tumor necrosis factor (TNF) — a key driver of inflammation in RA — in an animal model of endotoxemia. This finding was expanded in a 2002 paper that described the complete cholinergic anti-inflammatory pathway.

The pathway works as follows:

  • Vagal activation — Electrical stimulation of the vagus nerve activates efferent fibers traveling from the brainstem to the viscera.
  • Splenic nerve relay — Vagal signals are relayed through the celiac ganglion to the splenic nerve, which innervates the spleen — the body’s largest reservoir of immune cells.
  • Acetylcholine release from T cells — In a surprising twist, the neural signal does not directly release acetylcholine onto immune cells. Instead, the norepinephrine released by the splenic nerve activates a specific population of T cells (choline acetyltransferase-positive, or ChAT+ T cells) that themselves produce and release acetylcholine.
  • Alpha-7 nAChR activation — The acetylcholine released by these T cells binds to alpha-7 nicotinic acetylcholine receptors (alpha-7 nAChR) on macrophages and other innate immune cells.
  • Cytokine suppression — Activation of alpha-7 nAChR on macrophages suppresses the NF-kB signaling pathway, reducing the production of pro-inflammatory cytokines: TNF-alpha, interleukin-1-beta (IL-1-beta), interleukin-6 (IL-6), and high-mobility group box 1 (HMGB1). Importantly, anti-inflammatory cytokines like IL-10 are not suppressed, creating a selective anti-inflammatory effect.

This pathway is significant because it provides targeted immune modulation. Unlike immunosuppressive drugs that broadly suppress immune function (increasing infection risk), vagal stimulation acts specifically on the innate inflammatory response while leaving adaptive immunity (the ability to fight infections and respond to vaccines) largely intact.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

SetPoint Medical: The Clinical Program

SetPoint Medical, a bioelectronic medicine company co-founded by Kevin Tracey, has developed an implantable VNS device specifically designed to treat inflammatory diseases by activating the cholinergic anti-inflammatory pathway.

Device Design

The SetPoint device is smaller than traditional VNS systems used for epilepsy. It is implanted on the cervical vagus nerve and delivers brief, controlled electrical pulses designed to activate the anti-inflammatory pathway without the side effects (hoarseness, cough) associated with higher-intensity epilepsy VNS settings. Stimulation is typically delivered for a few minutes per day, a fraction of the continuous cycling used in epilepsy VNS.

Clinical Trial Results

Clinical data from SetPoint Medical’s RA program have shown encouraging results:

  • Proof-of-concept studies — Early clinical trials in patients with treatment-resistant RA demonstrated significant reductions in disease activity scores (DAS28-CRP), the standard measure of RA disease activity. Patients who had failed multiple biologic therapies showed meaningful clinical improvement.
  • Cytokine reductions — Blood tests confirmed reductions in circulating TNF, IL-6, and other pro-inflammatory cytokines following VNS treatment, consistent with the cholinergic anti-inflammatory pathway mechanism.
  • Sustained effects — Benefits were sustained over follow-up periods, with some patients maintaining improvement for years with continued daily stimulation.
  • Safety profile — The device was well-tolerated, with side effects generally limited to transient stimulation-related sensations. No increased infection rates were observed, in contrast to systemic immunosuppressive therapies.

The device received FDA Breakthrough Device designation, a pathway designed to accelerate the development and review of therapies for serious conditions where there is an unmet medical need.

How VNS Compares to Current RA Treatments

Understanding where VNS fits requires context about current RA therapeutics:

Conventional DMARDs (methotrexate, sulfasalazine, hydroxychloroquine) — First-line treatments that broadly suppress immune activity. Effective in many patients but carry risks of liver toxicity, bone marrow suppression, and increased infection susceptibility.

Biologic DMARDs (adalimumab, etanercept, rituximab, tocilizumab) — Targeted therapies that block specific inflammatory molecules (TNF, IL-6, B cells, T cell co-stimulation). More effective than conventional DMARDs in many patients but expensive (often exceeding $30,000-$50,000 per year) and associated with increased infection risk, including reactivation of tuberculosis.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) — Oral targeted therapies that block intracellular signaling pathways. Effective but carry cardiovascular and infection warnings.

VNS (bioelectronic medicine) — Modulates the immune response through the body’s own neural circuit. Does not suppress adaptive immunity, so infection risk is theoretically lower. Requires surgical implantation but provides ongoing treatment without daily medication. Currently investigational for RA.

Beyond RA: Other Inflammatory Conditions

The cholinergic anti-inflammatory pathway is not specific to RA. The same mechanism is being investigated for several other inflammatory conditions:

  • Crohn’s disease — Clinical trials have explored VNS for Crohn’s disease, with early results showing improvements in disease activity and reductions in inflammatory markers. The gut is densely innervated by the vagus nerve, making it a logical target.
  • Systemic lupus erythematosus (SLE) — Preclinical research suggests vagal stimulation may reduce the autoimmune inflammation characteristic of lupus.
  • Sepsis and acute inflammation — The original discovery of the cholinergic anti-inflammatory pathway arose from sepsis models, and VNS is being investigated as a potential adjunct treatment for life-threatening systemic inflammation.
  • Postoperative ileus — VNS may reduce the inflammatory paralysis of the gut that commonly follows abdominal surgery.

Current Status and Limitations

VNS for RA remains investigational and is not yet FDA-approved for this indication. Key considerations:

  • Clinical trials are ongoing, and larger pivotal studies are needed to confirm efficacy and support regulatory approval.
  • The treatment requires surgical implantation, which carries standard surgical risks (infection, bleeding, nerve injury).
  • Not all patients respond equally. The reasons for variable response are still being investigated, and biomarkers to predict response are under development.
  • The approach is not a replacement for existing RA therapies in all patients. It may be most valuable for patients who have failed or cannot tolerate multiple biologic therapies.
  • Cost and insurance coverage are uncertain, as the device has not yet received full FDA approval for inflammatory indications.

Despite these limitations, the VNS approach to RA represents one of the most significant conceptual shifts in inflammatory disease treatment: the idea that the nervous system can be harnessed to regulate the immune system, replacing chemical immunosuppression with targeted neural modulation.

The connection between the vagus nerve and the immune system is one of the most exciting areas of modern medicine. Get the My Vagus Nerve & Me eBook for a deep dive into the vagus nerve’s role in inflammation, immunity, and whole-body health.